You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 10,945,950


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,945,950 protect, and when does it expire?

Patent 10,945,950 protects OHTUVAYRE and is included in one NDA.

This patent has sixty-two patent family members in twenty-eight countries.

Summary for Patent: 10,945,950
Title:Liquid inhalation formulation comprising RPL554
Abstract:The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body.
Inventor(s):Spargo Peter Lionel, French Edward James, Haywood Phillip A.
Assignee:VERONA PHARMA PLC
Application Number:US15927517
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Analyzing the Scope and Claims of United States Patent 10,945,950

Introduction

United States Patent 10,945,950, titled "Liquid inhalation formulation comprising RPL554," is a patent that describes a specific pharmaceutical composition designed for inhalation. To understand the scope and claims of this patent, it is essential to delve into its various components, including the background, summary, detailed description, and the claims themselves.

Background

The patent in question pertains to a liquid pharmaceutical composition suitable for administration by inhalation. This type of formulation is crucial in the treatment of respiratory diseases, where targeted delivery of the active ingredient directly to the lungs can be highly effective.

Summary of the Invention

The invention described in US Patent 10,945,950 involves a liquid pharmaceutical composition that includes a diluent and a suspension of RPL554, a compound known for its therapeutic properties in treating respiratory conditions. The composition is designed to be administered via inhalation, ensuring the active ingredient is delivered directly to the lungs[4].

Detailed Description

Composition Components

The patent details the components of the liquid inhalation formulation:

  • RPL554: The active ingredient, which is a dual phosphodiesterase 3 and 4 inhibitor.
  • Diluent: A liquid carrier that helps in the suspension and delivery of RPL554.
  • Suspension: The formulation involves suspending RPL554 in the diluent to ensure uniform distribution and effective delivery[4].

Preparation and Administration

The patent describes the methods for preparing the formulation and its administration. This includes the process of mixing the components, ensuring the stability of the suspension, and the devices or methods used for inhalation.

Therapeutic Use

The therapeutic use of this formulation is highlighted, particularly in treating respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The direct delivery of RPL554 to the lungs enhances its efficacy and reduces systemic side effects[4].

Claims

Independent Claims

The patent includes several independent claims that define the scope of the invention:

  • Claim 1: This claim describes the liquid pharmaceutical composition comprising a diluent and a suspension of RPL554.
  • Claim 2: This claim specifies the concentration of RPL554 in the composition.
  • Claim 3: This claim details the method of preparing the formulation[4].

Dependent Claims

Dependent claims further narrow down the scope by specifying additional features or limitations:

  • Claim 4: This claim describes the type of diluent used.
  • Claim 5: This claim specifies the method of administration, such as using an inhaler[4].

Patent Scope and Breadth

Metrics for Measuring Patent Scope

Research on patent scope often uses metrics such as independent claim length and independent claim count to assess the breadth of a patent. Narrower claims at publication are associated with a higher probability of grant and a shorter examination process, indicating a more focused and well-defined invention[3].

Analysis of US Patent 10,945,950

  • Claim Length: The independent claims in this patent are relatively concise, indicating a clear and focused definition of the invention.
  • Claim Count: The number of claims is moderate, suggesting a balanced approach between breadth and specificity.
  • Forward Citations: The number of forward citations can indicate the impact and relevance of the patent. However, as this patent is relatively recent, it may not have accumulated significant forward citations yet.

International and Global Context

Global Dossier

For patents like US 10,945,950, the Global Dossier service provided by the USPTO allows users to view the patent family for a specific application, including related applications filed at participating IP Offices. This helps in understanding the global landscape and potential variations of the invention[1].

Search International Patent Offices

To ensure the novelty and non-obviousness of the invention, it is crucial to search international patent databases such as those provided by the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO)[1].

Legal and Practical Considerations

Patent Litigation and Licensing

The scope and claims of a patent can significantly impact litigation and licensing costs. Broader claims may lead to increased litigation risks, while narrower claims can provide clearer boundaries and reduce disputes[3].

Small Claims Patent Court

The concept of a small claims patent court, as studied by the Administrative Conference of the United States (ACUS), could potentially affect how disputes related to patents like US 10,945,950 are resolved. Such a court could provide a more streamlined and cost-effective process for resolving patent disputes[5].

Key Takeaways

  • Clear and Focused Claims: The patent's claims are concise and well-defined, indicating a clear scope of the invention.
  • Therapeutic Use: The formulation is specifically designed for treating respiratory diseases, highlighting its therapeutic value.
  • Global Context: Understanding the global patent landscape through services like Global Dossier is crucial for managing intellectual property.
  • Legal Implications: The scope and claims of the patent can have significant legal and practical implications, including litigation and licensing costs.

FAQs

Q: What is the main active ingredient in the liquid inhalation formulation described in US Patent 10,945,950?

A: The main active ingredient is RPL554, a dual phosphodiesterase 3 and 4 inhibitor.

Q: How is the liquid inhalation formulation administered?

A: The formulation is administered via inhalation, typically using an inhaler.

Q: What are the therapeutic uses of this formulation?

A: The formulation is used to treat respiratory diseases such as COPD and asthma.

Q: How can one search for related international patents?

A: One can use services like Global Dossier and search international patent databases provided by offices such as the EPO, JPO, and WIPO.

Q: What are the potential legal implications of the scope and claims of this patent?

A: The scope and claims can affect litigation and licensing costs, with broader claims potentially leading to increased litigation risks.

Sources

  1. USPTO: Search for patents - USPTO.
  2. USA.gov: U.S. Patent and Trademark Office (USPTO) | USAGov.
  3. SSRN: Patent Claims and Patent Scope.
  4. Google Patents: US10945950B2 - Liquid inhalation formulation comprising RPL554.
  5. ACUS: U.S. Patent Small Claims Court.

More… ↓

⤷  Subscribe


Recent additions to Drugs Protected by US Patent 10,945,950

These patents are from the daily update and have not yet been integrated into the regular database
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Product Substance Delist Req. Patent Expiration Usecode Patented / Exclusive Use
Verona Pharma OHTUVAYRE ensifentrine SUSPENSION 217389 Jun 26, 2024 RX Yes 10,945,950 Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Type >RLD >Patent No. >Product >Substance >Delist Req. >Patent Expiration >Usecode >Patented / Exclusive Use

Drugs Protected by US Patent 10,945,950

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Verona Pharma OHTUVAYRE ensifentrine SUSPENSION;INHALATION 217389-001 Jun 26, 2024 RX Yes Yes 10,945,950 ⤷  Subscribe Y ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,945,950

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015316592 ⤷  Subscribe
Australia 2018286571 ⤷  Subscribe
Australia 2020203081 ⤷  Subscribe
Brazil 112017005050 ⤷  Subscribe
Canada 2959943 ⤷  Subscribe
China 106794157 ⤷  Subscribe
China 110051627 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.